|Articles|March 1, 2018
- BioPharm International-03-01-2018
- Volume 31
- Issue 3
BioPharm International, March 2018 Issue (PDF)
Click the title above to open the BioPharm International March 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
almost 8 years ago
FDA Heightens Drive for Transparencyalmost 8 years ago
Current Challenges in Bioprocesses Developmentalmost 8 years ago
Characterizing a Bioprocess with Advanced Data Analyticsalmost 8 years ago
Computerized Systems Validationalmost 8 years ago
Regulatory Role in Bio/Pharma Progressalmost 8 years ago
Poseidon Takes on the Pharma Supply Chainalmost 8 years ago
Identifying and Controlling CPPs and CMAsalmost 8 years ago
Employing Spectroscopic Tools in Downstream Process Controlalmost 8 years ago
Biologic NMEs Maintain Strong Presence in 2017 Drug ApprovalsNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
How CDMO Alliances Can Provide End-to-End Service that Reduces Drug Development Time and Costs
2
First-in-Human Study Validates Safety of Next-Generation mRNA–LNP Platform
3
Industry Outlook 2026: Key Forces Transforming Drug Pipelines (Part 2)
4
Eli Lilly Announces New $3.5 Billion Manufacturing Facility in Pennsylvania
5
